Q1 Earnings deliver 10% sales growth, 46% margins, $8.1B FCF
Key Questions
What were the key financial results from Amgen's Q1 earnings call?
Amgen reported 10% sales growth for 2025, 46% non-GAAP margins, and $8.1 billion in free cash flow, demonstrating strong execution post-Prolia loss of exclusivity.
Which products are contributing to Amgen's growth according to the earnings?
Growth aligns with ramps in TEPEZZA and Repatha, along with MariTide potential, despite biosimilar and antitrust risks.
What recent analyst ratings and price targets were issued for Amgen?
Canaccord Genuity initiated coverage with a Hold rating and $366 price target, while Bernstein maintained a Hold at $335. Consensus price targets range from $353-358.
How has Amgen's stock performed recently, and what technical indicators are noted?
The stock dipped to $339 but rallied to $355, appearing undervalued on P/E and PEG ratios, with technical analysis showing an RSI uptrend.
What is the current status of this earnings highlight?
The highlight status is cooling.
Earnings call highlights strong execution post-Prolia LOE with 10% '25 sales growth, 46% non-GAAP margins, $8.1B FCF. Aligns with TEPEZZA/Repatha ramps and MariTide potential amid biosims/antitrust risks. Bullish rally to $355; new Goldman Buy $33 PT (outlier low), Market Perform downgrade amid Canaccord $366/Bernstein $335 Holds/cons $353-358; TA RSI uptrend.